Inamed Breast Implant Panel Nod Helps Boost Stock 31% In March
This article was originally published in The Gray Sheet
Executive Summary
Inamed stock enjoyed a 31% price jump in March to 49-1/2 as a favorable recommendation by an FDA panel reassured investors that the McGhan division's saline breast implants would remain on the market.
You may also be interested in...
B&L Looking To Enter Cosmetic Lens Market Via Wesley Jessen Acquisition
Bausch & Lomb's unsolicited offer for cosmetic contact lens manufacturer Wesley Jessen VisionCare will have to take into account a $20 mil. one-time charge the latter will face if it walks away from a previously announced definitive merger agreement with Ocular Sciences.
Panel Urges McGhan To Recharacterize "Inflated" Complication Rates
Inamed's McGhan Medical unit should eliminate non-significant risks from its risk characterization of saline breast implants as a condition for FDA approval, the agency's General and Plastic Surgery Devices advisory panel concluded March 2 in Gaithersburg, Maryland.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.